Full-Life Technologies announced the completion of a US$150 million financing package comprised of approximately US$110 million in Series D equity financing and US$40 million in debt financing. The financing round was led by Vivo Capital and included participation from strategic partner SK Biopharmaceuticals along with Chengwei Capital, HSG, Junson Capital, Yunion, Plaisance, Sky9 Capital, TSG Capital, and other shareholders.
The proceeds from the financing will support the advancement of Full-Life’s clinical-stage radiotherapeutics pipeline, including potential best-in-class [225Ac]-FL-020 for prostate cancer and potential first-in-class [225Ac]-FL-261 for multiple solid tumor indications. The company expects to have three differentiated clinical-stage programs by the end of 2026, all originating from its UniRDC discovery platform.
The funding will also support the launch of GMP-grade 225Ac manufacturing operations at Full-Life’s facility in Belgium. The company said controlling isotope supply and manufacturing internally provides a strategic advantage for accelerating radiotherapeutics development through clinical stages and toward commercialization.
Founded in 2021, Full-Life has now secured nearly US$350 million in total funding through a combination of equity and debt financing.
KEY QUOTES:
“Full-Life is distinguished not only by their scientific vision, but their ability to translate it into tangible clinical and operational milestones at a global scale. We are impressed by their early discovery efficiency, the strong emerging data from their lead program, and the accelerated progress of their manufacturing facility in Belgium. Leading this Series D financing reflects our conviction that Full-Life is transitioning from a platform innovator to a fully integrated radiopharmaceutical company, and we are excited to support their next phase of value creation.”
Hao Dong, Managing Director, Vivo Capital
“This financing reflects the significant value we have created over the past four years, evolving from a platform builder to a clinical-stage company. With the strong momentum from our lead asset, and the rapid advancement of our pipeline assets, this funding will accelerate our transition toward late-stage development and ensure our Belgium GMP facility is fully operational to support global 225Ac commercial supply.”
Julie Wu, President And Chief Financial Officer, Full-Life Technologies
